Clinical data | |
---|---|
Other names | Pyrroxane, Pirroksan |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H23NO3 |
Molar mass | 337.419 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Proroxan (INN; also known as pyrroxane and pirroksan) is a pharmaceutical drug used as an antihypertensive and in the treatment of Ménière's disease, motion sickness, and allergic dermatitis.
Proroxan is a non-selective alpha-blocker (α-adrenoreceptor antagonist).
Proroxan was developed in the 1970s at the Institute of Toxicology of the USSR Ministry of Health and today is primarily used in Russia. Though originally developed as an antihypertensive, its use can lead to a decrease in alcohol and drug consumption. Currently proroxan is used almost exclusively in psychiatry, narcology, and neurology.
References
- ^ "Proroxan hydrochloride". Inxight Drugs. National Institutes of Health.
- "ПРОРОКСАН (PROROXAN) ОПИСАНИЕ". vidal.ru.
- ^ Shabanov PD (2020). "Clinical pharmacology of pyrroxane (proroxane)". Reviews on Clinical Pharmacology and Drug Therapy (in Russian). 18 (4): 335–350. doi:10.17816/RCF184335-350. S2CID 234440112.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |